Pharma Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bioterrorism
Milestone reached in the development and manufacture of RiVax
August 15th, 2005
BioPharma, Inc. (DOR) and a subsidiary of Cambrex Corp. (CBM) announced that they have successfully achieved, ahead of schedule, the first milestone of fermentation and downstream process development in their development and manufacturing agreement for RiVax, DOR's ricin toxin vaccine. DOR and Cambrex entered into an agreement in January, 2005, under which Cambrex would provide process development and cGMP (current Good Manufacturing Processes) production services for the development and manufacture of clinical quantities of RiVax. The companies' work has been conducted under a challenge grant totaling $6.4 million awarded to DOR in September, 2004,...
Source: Pharma Business Week (2005-08-15)
|
